No Data
Warner Pharmaceuticals (688799.SH): The Active Pharmaceutical Ingredient of its subsidiary has received the approval notice for its listing application.
On December 23, Gelonghui announced that Warner Pharmaceutical (688799.SH) disclosed that its wholly-owned subsidiary Hunan Warner Large Pharmaceutical Co., Ltd. received the "Approval Notice for the Market Application of Chemical Raw Materials" issued by the National Medical Products Administration for Diquafosol Sodium and Methoxamine Tartrate, and the information was publicized on the "Raw Materials, Pharmaceutical Excipients and Packaging Materials Registration Information Publicity" platform of the CDE. Diquafosol Sodium is a P2Y2 receptor agonist. Diquafosol Sodium is a dinucleotide derivative that acts on conjunctival tissues and the membranes of goblet cells via the P2Y2 receptor, affecting intracellular activities.
Warner Pharmaceutical (688799.SH): Huang Bendong elected as Director.
On December 20, Gelonghui announced that Warner Pharmaceuticals (688799.SH) has elected the members of its fourth Board of Directors at the third extraordinary Shareholders' Meeting of 2024. In accordance with the relevant provisions of the Company Law, Articles of Association, and other laws and regulations, the fourth Board of Directors of the company approved the election of Mr. Huang Bendong as the Chairman of the fourth Board of Directors, with a term starting from the date of approval at this meeting until the end of the term of the fourth Board of Directors.
Hunan Warrant Pharma Completes Phase 2 Trial for Respiratory Traditional Chinese Drug
Warner Pharmaceutical (688799.SH) has received the summary report of the Phase II clinical trial for Qianqing granules.
Warner Pharmaceuticals (688799.SH) announced that the research project Qianqing granules has been approved by the National Medical Products Administration...
Wanah Pharmacy (688799.SH): plans to launch a restricted stocks incentive plan of 3.41 million shares.
Grain News December 4th | Warner Pharma (688799.SH) announced the 2024 restricted stocks incentive plan, with the plan proposing to grant 3.41 million restricted stocks to incentive recipients, accounting for approximately 3.64% of the company's total share capital of 93.8 million shares on the date of the plan announcement. This grant is a one-time grant with no reserved rights.
Warner Pharmaceutical Factory (688799.SH): Xu Xiaoqiang and Xu Yuehan plan to collectively reduce their shareholding by no more than 1.352 million shares.
Gelonghui on December 2nd: Warner Pharmaceutical Factory (688799.SH) announced that shareholders Mr. Xu Xiaoqiang and Ms. Xu Yuehan plan to reduce their shareholdings in the company by a total of no more than 1,352,000 shares due to their own financial needs. Among them, they plan to reduce their shareholdings by no more than 938,000 shares through the trading method, not exceeding 1% of the total share capital of the company; they plan to reduce no more than 1,352,000 shares through block trading, that is, no more than 1.44% of the total share capital of the company.
Hunan Warrant Pharmaceutical Co.,Ltd's (SHSE:688799) Shares Bounce 43% But Its Business Still Trails The Market
